ClinicalTrials.gov
ClinicalTrials.gov Menu

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00492336
Recruitment Status : Completed
First Posted : June 27, 2007
Results First Posted : June 19, 2013
Last Update Posted : April 20, 2018
Sponsor:
Collaborator:
Stanley Medical Research Institute
Information provided by (Responsible Party):
Robert W. Buchanan, University of Maryland

Brief Summary:
This is a study of a new medication for the treatment of cognitive impairments (thinking difficulties) and negative symptoms in people with schizophrenia. The new medication is rasagiline. Rasagiline is a drug which has been approved by the Food and Drug Administration for the treatment of Parkinson's disease. It is used to treat cognitive problems.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: rasagiline (Pharmacodynamics) Drug: Placebo Phase 4

Detailed Description:
The study will consist of two phases: a 4-week continued stability phase (lead-in phase) and a 12-week double-blind treatment phase. In the lead-in phase, subjects receiving antipsychotic medication, who manifest moderate to severe and persistent negative symptoms, will remain on their maintenance regimen for at least four weeks. The treatment phase will be a 12-week, parallel groups, double-blind, placebo-controlled trial of adjunctive rasagiline (1 mg/day), a selective MAO-B oxidase inhibitor.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
Study Start Date : January 2007
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Active Comparator: Rasagiline
Treatment with Rasagiline
Drug: rasagiline (Pharmacodynamics)
Rasagiline 1 mg/day for 12 weeks

Placebo Comparator: Inactive pill
Treatment with Placebo
Drug: Placebo
Placebo 1 tablet each day




Primary Outcome Measures :
  1. Change in Negative Symptoms [ Time Frame: Every 4 weeks over a 12 week period ]
    The Scale for the Assessment of Negative Symptoms (SANS) rating scale was used to assess the negative symptoms of schizophrenia. Scores on the subscales are combined (summed) to compute a total score. There are a total of 17 subscales. Each subscale ranges from 0="Not at all" to 5="Severe". Every 4 weeks the summed subscale scores provide a total score for that week (0-85). Higher scores indicate more severe negative symptoms.

  2. Cognitive Testing - Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score [ Time Frame: Beginning of treatment phase (week 0) and end of treatment phase (week 12) ]
    The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160.

  3. Cognitive Testing - N-Back Neurocognitive Task [ Time Frame: Beginning of treatment phase (week 0) and end of treatment phase (week 12) ]
    The N-Back task is a sequential letter working memory task. D-prime was used to measure accuracy on the 0-back, 1-back, and 2-back conditions. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.

  4. Cognitive Testing - Probabilistic Learning Task [ Time Frame: Beginning of treatment phase (week 0) and end of treatment phase (week 12) ]
    To assess reward learning, participants used performance feedback to choose the most frequently rewarded item in each of three pairs of stimuli (one pair had reward probabilities: 80% vs 20%; one pair had reward probabilities of 70% vs 30%; one pair had the probabilities of 60% vs 40 %) (PL; Frank et al, 2004). A total of 240 trials were administered so each pair was seen 80 times. Higher scores represent more frequent choices of the optimal stimulus in each pair. The frequencies with which participants repeated an item choice that was rewarded on the previous presentation (win-stay) is also presented as a percentage. Similarly, the lose-shift score is the percentage of times that participants changed their choice for unrewarded items (lose-shift). The win-stay score serves as a measure of the impact of positive feedback on subsequent choices while the lost-shift score serves as a measure of the impact of negative feedback on subsequent choices.

  5. Cognitive Testing - Delayed Discounting [ Time Frame: Beginning of treatment phase (week 0) and end of treatment phase (week 12) ]
    The monetary choice questionnaire for hypothetical monetary rewards was used to assess delayed discounting (Kirby et al, 1999). The measure includes 27 items in which participants choose between a smaller, immediate reward (SIR) and a larger, delayed reward (LDR). There are three LDR sizes: small ($25-35), medium ($50-60) and large ($75-85). By examining the pattern of choices that participants make across the set of 27 items it is possible to calculate their delay discounting rate, termed K. The discount rate determines the steepness of the reduction in the present value of a reward with increases in the delay to the possible receipt of that reward. Thus, higher values in K represent greater discounting of the value of future rewards. With this measure K values can range between a low of 0.00016 to a high of 0.25. Higher K values have been linked to measures of impulsivity. Shown in the table are the K values observed when the future rewards were small, medium, or large.


Secondary Outcome Measures :
  1. Extrapyramidal Symptoms [ Time Frame: Baseline (Week 0) and End of Study (Week 12) ]
    The Simpson Angus Scale (SAS; Simpson and Angus, 1970) was used to assess extrapyramidal symptoms (EPS). The assessment consists of 11 items, each rating the severity of potential symptoms of movement disorders. Total scores are calculated by summing the scores of each of the 11 items for a potential total score of 0-44, with higher scores indicating more severe EPS.

  2. Number of Participants With Akathisia [ Time Frame: Baseline and every two weeks throughout the double-blind phase of the study, for up to 12 weeks. ]
    The Barnes Akathisia Scale (BAS; Barnes, 1989) was used to assess akathisia, a type of extrapyramidal symptom. The global clinical assessment of akathisia score is rated on a scale from 0=Absent to 5=Severe Akathisia.

  3. Change in Persistent Positive Symptoms [ Time Frame: Every 4 weeks for 12 weeks. ]
    The Brief Psychiatric Rating Scale (BPRS) positive symptom item total score was used to assess positive symptom change. The BPRS positive symptom items are: conceptual disorganization, hallucinatory behavior, unusual thought content, and suspiciousness. The total score is calculated by adding the scores for each item. Each scale ranges from "1=Not Present" to "7=Very Severe". The minimum score is 4 and the maximum score is 28. A higher score indicates a more severe positive symptom rating.

  4. Depressive Symptoms [ Time Frame: Every 4 weeks for 12 weeks. ]
    The Calgary Depression Scale (CDS; Addington et al, 1997) total score was used to assess depressive symptoms over the course of the study. Total scores were calculated by summing the scores of each of the 9 items. Total scores can range from 0-27, with higher scores indicating more severe depressive symptoms.

  5. Global Change in Illness Severity [ Time Frame: Every 4 weeks for 12 weeks. ]
    The Clinical Global Impression (CGI) severity of illness item was used to assess global changes. Scores on this item range from 1="Normal, not at all ill" to 7="Among the most extremely ill".

  6. Number of Participants Exhibiting Side Effects [ Time Frame: Every week for 12 weeks ]
    The Side Effect Checklist (SEC) was used to assess side effects. The SEC is comprised of 22 common side effects, which are rated on a 1 (none)-4 (severe) scale. Side effects are determined to be clinically significant if there is a two or more point increase in severity from baseline, or any side effect that receives a severity rating of "4" (severe) at any point in the treatment phase of the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will meet DSM-IV criteria for schizophrenia or schizoaffective disorder.
  • Current treatment with one or more second generation antipsychotics, except ziprasidone
  • On same second generation antipsychotic(s)for at least 56 days
  • On same dose of second generation antipsychotic(s)for at least 30 days
  • 22-item SANS: Total score (i.e.all items minus global items and poverty of content of speech)greater than 20 or global Rating of Affective Flattening greater than or equal to 3 or global Rating of alogia greater than or equal to 3
  • BPRS: Sum of the four positive symptom items less than or equal to 16 (items 4,11,12,15)
  • BPRS: Sum of the four Anxiety/Depression Factor items less than or equal to 14 (items 1,2,5,9)
  • Simpson-Angus Scale: Total score less than or equal to 8

Exclusion Criteria:

  • DSM-IV Major Depressive Disorder within last 6 months
  • Current treatment with ziprasidone
  • DSM-IV diagnosis of alcohol or substance dependence within the last 6 months
  • DSM-IV criteria for alcohol or substance abuse within the last month
  • evidence of illicit substance use, as identified with urine toxicology screen
  • History of an organic brain disorder, mental retardation,epilepsy, or a medical condition, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol. See those listed below
  • Uncontrolled hypertension defined as BP exceeding 145/90 on 3 consecutive readings despite adequate treatment, pheochromocytoma, melanoma, hepatic insufficiency
  • Pregnancy or lactation in females
  • Pheochromocytoma
  • Melanoma
  • Hepatic insufficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00492336


Locations
United States, Maryland
Baltimore VA Medical Center
Baltimore, Maryland, United States, 21201
Keypoint Mental health Center
Catonsville, Maryland, United States, 21228
Maryland Psychiatric REsearch Center
Catonsville, Maryland, United States, 21228
Mosaic Community Mental health Center
Catonsville, Maryland, United States, 21228
Keypoint Mental health Center
Dundalk, Maryland, United States, 21222
Sponsors and Collaborators
University of Maryland
Stanley Medical Research Institute
Investigators
Principal Investigator: Robert W Buchanan, M.D. University of Maryland

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Robert W. Buchanan, Chief, Maryland Psychiatric Research Center, Outpatient Research Program, University of Maryland
ClinicalTrials.gov Identifier: NCT00492336     History of Changes
Other Study ID Numbers: HP-00043807
H-27877 ( Other Identifier: University of Maryland Baltimore )
First Posted: June 27, 2007    Key Record Dates
Results First Posted: June 19, 2013
Last Update Posted: April 20, 2018
Last Verified: June 2013

Keywords provided by Robert W. Buchanan, University of Maryland:
Cognitive impairments
Negative symptoms

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Rasagiline
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs